Investors Overview

Overview

Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.




Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

11 Jul '24
REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan
03 Jul '24
Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. Attachment Managers Transaction CSSF Form - ATP Holdings ehf 20240702
03 Jul '24
Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding a "notification of major holdings" in Alvotech by Aztiq Pharma Partners S.a r.l. and ATP Holdings ehf. On July 1, 2024 the shareholder acquired 2,587,089 additional ordinary shares in Alvotech

Recent Events